Fast Market Research

"EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022" Is Now Available at Fast Market Research

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

 
Repost This

Boston, MA -- (SBWIRE) -- 12/11/2013 -- Urinary tract infections (UTIs) are among the most common bacterial infections acquired in hospitals and in the community setting. A UTI can occur when daily living activities and medical interventions aid in the movement of bacteria into the urethra; however, bacterial colonization does not always lead to the development of UTI symptoms. Although UTIs can be caused by bacteria, viruses, or fungi, gram-negative bacteria are the pathogens most frequently associated with UTIs. Gram-negative bacteria have become increasingly resistant to individual antimicrobials, and of particular concern, is the emergence of multidrug-resistant activity in these organisms. Although there has been little change in the predominant causative pathogens in the past few decades, individual pathogen frequency and resistance patterns of gram-negative pathogens vary considerably between settings, countries, and continents.

View Full Report Details and Table of Contents

According to GlobalData's forecast, the number of incident cases of UTI will increase in the US during the forecast period. The largest number of cases will be classified as community-acquired and occur in women =80 years of age. The 5EU will see a slight increase in the number of healthcare-associated incident cases of UTI during the forecast period, with the highest number of cases occurring among women in Germany, and among those ages 70-79 years. Japan is forecast to see a large increase in the number of incident cases of UTI occurring during the forecast period in intensive care units, with the greatest number of cases occurring among women and those =80 years.

A major strength of this analysis is that GlobalData epidemiologists used country-specific sources for each market in the analysis and were able to obtain country-specific national surveillance data for the 5EU and Japan. The use of country-specific sources is especially important for antimicrobial resistance data as the rates of resistance have been found to vary considerably between countries. Additionally, because resistance rates have changed over time, GlobalData's use of recent sources for resistance rates ensures that the estimates for the number of resistant cases of UTI reflect the most current situation in each market.

Scope

- The Gram-Negative Bacterial Urinary Tract Infection (UTI) EpiCast Report provides an overview of the risk factors and global trends of UTI in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of UTI incident cases segmented by age (0-85 years and older), sex, causative pathogen (Escherichia coli, Klebsiella, Pseudomonas aeruginosa, Proteus, and Acinetobacter), multidrug resistance, and carbapenem resistance in these markets.
- The UTI epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022
- EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022
- EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
- EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022
- EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
- EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022
- EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
- EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022